All posts tagged
CAR-T Competition Heats Up with a New IND Approval
A Cure for Cancer? How CAR-T Therapy is Revolutionizing Oncology
The 10 Biggest Clinical Success Stories of 2016 in European Biotech
Debunking the Immuno-Oncology Hype: is it as good as it sounds?
Cellectis gets paid for a first Milestone, Investors are pleased
Universal CAR-T given to Second baby with aggressive Leukemia
How Good was 2015 for the French Universal CAR-T Biotech?
The European Union Finances the Future of CAR-T Manufacturing
Cellectis has Discovered an ‘On-Switch’ to Make CAR-T Safer and Better Controlled
Cellectis Full-Steam Ahead with UCART19 Trial for Leukemia in the UK
CAR-T Phase II: 93% Complete Remission in Children with Relapsed Leukemia!
Why has the Universal CAR-T Treatment For Leukemia Hooked TWO Big Pharmas at Once?
Labiotech UG, All Rights Reserved -
Send this to friend